drugset / Trial / NCT03111615

HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer

NCT03111615

Phase 4 Unknown 90 enrolled Centro Hospitalar Lisboa Ocidental
RandomizedParallel-groupTriple-blindTreatment

Summary

Breast Cancer is a public health issue worldwide. The time from diagnosis to treatment initiation varies from country to country and regionally within a country. Early diagnosis and prompt treatment initiation are key factors in patient survival rates. Currently there is a rising trend, with a high percentage of patients with "Luminal" like breast cancer only undergoing adjuvant endocrine therapy. Authors argue that tumor biology alterations after introducing very early endocrine therapy might have a prognostic and therapeutic impact and should be studied.

Timeline

Start
2018-05-01
Primary completion
2019-05-01
Completion
2020-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg
Subject Letrozole Other / unclassified 2.5 mg